Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisal.

Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisal.

Show other versions (1)

As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of rituximab (Roche Products) to submit evidence of the clinical and cost effectiveness of rituximab in combination with corticosteroids for treatment of an...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron:	Latimer, N, Carroll, C, Wong, R, Tappenden, P, Venning, M, Luqmani, R
Fformat:	Journal article
Iaith:	English
Cyhoeddwyd:	2014

Eitemau Tebyg

Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal
gan: Latimer, N, et al.
Cyhoeddwyd: (2014)

Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis.
gan: Guerry, M, et al.
Cyhoeddwyd: (2012)

Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?
gan: Flossmann, O, et al.
Cyhoeddwyd: (2006)

Successful use of rituximab for hydralazine-induced anti-neutrophil cytoplasmic antibodies-associated vasculitis
gan: Michael A Paley, et al.
Cyhoeddwyd: (2019-01-01)

Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis
gan: Robson, J, et al.
Cyhoeddwyd: (2017)

Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis.
gan: Basu, N, et al.
Cyhoeddwyd: (2014)

Global ethnic and geographic differences in the clinical presentations of anti-neutrophil cytoplasm antibody-associated vasculitis
gan: Pearce, F, et al.
Cyhoeddwyd: (2017)

Eosinophils in anti-neutrophil cytoplasmic antibody associated vasculitis
gan: Thomas Hellmark, et al.
Cyhoeddwyd: (2019-03-01)

Anti-neutrophil cytoplasmic antibody associated vasculitis following rituximab: Outcomes of 50 patients in a tertiary single centre
gan: Fahidah Alenzi, et al.
Cyhoeddwyd: (2023-09-01)

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in Kidney Transplantation
gan: Valentina Binda, et al.
Cyhoeddwyd: (2021-12-01)

Relapse in Anti-Neutrophil Cytoplasm Antibody (ANCA)–Associated Vasculitis
gan: Alan D. Salama
Cyhoeddwyd: (2020-01-01)

Drug-induced anti-neutrophil cytoplasmic antibody-associated vasculitis
gan: Cheng-Hua Weng, et al.
Cyhoeddwyd: (2019-12-01)

A disease-specific patient-reported outcome for anti-neutrophil cytoplasmic antibody–associated vasculitis: scale structure and measurement properties of the anti-neutrophil cytoplasmic antibody-associated vasculitis patient-reported outcome measure
gan: Robson, J, et al.
Cyhoeddwyd: (2017)

Is rituximab “The Wonder Drug” for antineutrophil cytoplasmic antibodies-associated vasculitis?
gan: Saket Jha, et al.
Cyhoeddwyd: (2019-01-01)

Posterior scleritis with anti-neutrophil cytoplasmic antibody-associated vasculitis utilizing rituximab therapy to maintain remission: A case report
gan: Xinyu Weng, et al.
Cyhoeddwyd: (2022-03-01)

Cardiovascular and Cerebrovascular Outcomes in Anti-neutrophil Cytoplasmic Antibody-Associated Vasculitis
gan: Shiyu Xiao, et al.
Cyhoeddwyd: (2024-01-01)

Clonal hematopoiesis in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis
gan: Christopher Maximilian Arends, et al.
Cyhoeddwyd: (2020-06-01)

Anti-neutrophil cytoplasmic antibody associated vasculitis in patients with rheumatoid arthritis
gan: Haiting Wu, et al.
Cyhoeddwyd: (2022-04-01)

A glance into the future of anti-neutrophil cytoplasmic antibody-associated vasculitis
gan: Marta Casal Moura, et al.
Cyhoeddwyd: (2022-11-01)

Pathogenesis and pathology of anti-neutrophil cytoplasmic antibody（ANCA）-associated vasculitis
gan: Daisuke Tsukui, et al.
Cyhoeddwyd: (2021-01-01)

EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.
gan: Hellmich, B, et al.
Cyhoeddwyd: (2007)

Highly Sensitive Flow Cytometric Detection of Residual B-Cells After Rituximab in Anti-Neutrophil Cytoplasmic Antibodies-Associated Vasculitis Patients
gan: Laura S. van Dam, et al.
Cyhoeddwyd: (2020-12-01)

Use of a computerised system to facilitate evaluation of anti-neutrophil cytoplasm (ANCA Associated) vasculitis (AAV) and other forms of systemic vasculitis
gan: Luqmani, R, et al.
Cyhoeddwyd: (2017)

The role of neutrophils in vasculitis associated with antineutrophil cytoplasmic antibodies
gan: E. N. Vorkel, et al.
Cyhoeddwyd: (2024-12-01)

Application of biological agents in the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis
gan: Weijun Liu, et al.
Cyhoeddwyd: (2024-05-01)

Recent advances in the diagnosis and treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis
gan: Si-wei Tang, et al.
Cyhoeddwyd: (2024-03-01)

Oral Microbiota Profile in Patients with Anti-Neutrophil Cytoplasmic Antibody–Associated Vasculitis
gan: Anders Esberg, et al.
Cyhoeddwyd: (2022-08-01)

Late Onset of Rivaroxaban-Associated Anti-Neutrophil Cytoplasmic Antibody–Associated Vasculitis
gan: Muskan Agarwal MD, et al.
Cyhoeddwyd: (2023-10-01)

A case of Sjögren syndrome and anti-neutrophil cytoplasmic antibody-associated vasculitis
gan: K. Kaynar, et al.
Cyhoeddwyd: (2023-07-01)

Testicular granulomatous vasculitis mimicking testicular torsion in an anti-neutrophil cytoplasmic antibody–associated vasculitis patient
gan: Liye Suo, et al.
Cyhoeddwyd: (2019-01-01)

Clinical significance of HEp-2 cell cytoplasmic patterns in anti-neutrophil cytoplasmic antibody associated vasculitis
gan: Naidan Zhang, MS, et al.
Cyhoeddwyd: (2022-06-01)

Clinical features of anti-neutrophil cytoplasmic antibody-associated systemic vasculitis in French children
gan: Salomon R, et al.
Cyhoeddwyd: (2011-09-01)

Anti-myeloperoxidase IgM B cells in anti-neutrophil cytoplasmic antibody-associated vasculitis
gan: CM Wortel, et al.
Cyhoeddwyd: (2025-02-01)

Glucocorticoid Minimization in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: An International Survey of Clinicians
gan: David Massicotte-Azarniouch, et al.
Cyhoeddwyd: (2024-08-01)

Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis.
gan: Mukhtyar, C, et al.
Cyhoeddwyd: (2006)

Severe Infections following Rituximab Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
gan: Zhi-Ying Li, et al.
Cyhoeddwyd: (2020-08-01)

Spotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectives
gan: Moog P, et al.
Cyhoeddwyd: (2015-11-01)

Neutrophil activation in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis and large-vessel vasculitis
gan: Despina Michailidou, et al.
Cyhoeddwyd: (2022-06-01)

Positive predictive value of anti-neutrophil cytoplasmic antibody (ANCA) testing for ANCA-associated systemic vasculitis (AASV) in a routine clinical setting
gan: McLaren, J, et al.
Cyhoeddwyd: (2001)

Anti-neutrophil cytoplasmic antibody–associated vasculitis complicated with diffuse alveolar haemorrhage and central nervous system vasculitis
gan: Takashi Nawata, et al.
Cyhoeddwyd: (2021-04-01)